Title :

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.

Author(s) :

Hupé, M. [Auteur]
Streichenberger, A. [Auteur]
Wils, P. [Auteur]
Hôpital Claude Huriez [Lille]
Arab, N. [Auteur]
Serrero, M. [Auteur]
Amiot, A. [Auteur]
Bozon, A. [Auteur]
Vuitton, L. [Auteur]
Fumery, M. [Auteur]
Altwegg, R. [Auteur]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hébuterne, X. [Auteur]
Yzet, C. [Auteur]
Coban, D. [Auteur]
Dodel, M. [Auteur]
Bazoge, M. [Auteur]
Pereira, B. [Auteur]
Buisson, A. [Auteur]
Service Hépato-Gastro-Entérologie [CHU Clermont-Ferrand]
Wils, P. [Auteur]

Journal title :

Digestive and Liver Disease

Abbreviated title :

Dig Liver Dis

Volume number :

56

Pages :

1312-1318

Publisher :

Elsevier

Publication date :

2024-02-03

ISSN :

1878-3562

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. Aims To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous ...
Show more >Background Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. Aims To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent. Methods In this multicenter retrospective study (8 centers), we included all consecutive UC patients with prior exposure to subcutaneous anti-TNF, starting infliximab for symptomatic UC, excluding acute severe colitis. Corticosteroid-free clinical remission (CFREM) was assessed at week 14 (W14) and W52 while endoscopic improvement (CFREM + endoscopic Mayo score≤1) was evaluated at W14. Results Overall, 104 patients were included (pancolitis=54.8%, primary failure to subcutaneous anti-TNF=57.4%, concomitant immunosuppressant=53.8%, median partial Mayo score at baseline=7[5–8]). The rate of CFREM was 33.6% (35/104) at W14 and 40.4% (42/104) at W52. At W14, endoscopic improvement was achieved in 29.8%(31/104). In multivariable analysis, concomitant immunosuppressant was associated with higher rate of CFREM at W14(OR=2.83[1.06–7.54], p = 0.037) and W52(OR=2.68[1.16–6.22];p = 0.021), while primary failure to a previous subcutaneous anti-TNF agent led to lower rate of CFREM at W14 (OR=0.37[0.14–0.98], p = 0.046). After a median follow-up of 20.9 months[11.7–33.7]), 50.0%(52/104) patients had discontinued infliximab. Conclusion Infliximab is an effective option in UC patients previously exposed to prior subcutaneous anti-TNF agent and should be used with concomitant immunosuppressant.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-06T22:03:23Z
2024-09-04T09:37:53Z